-
1
-
-
4744337716
-
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
-
Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-20.
-
(2004)
N Engl J Med
, vol.351
, pp. 1513-1520
-
-
Petrylak, D.P.1
Tangen, C.M.2
Hussain, M.H.3
-
2
-
-
4744366279
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
-
Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-12.
-
(2004)
N Engl J Med
, vol.351
, pp. 1502-1512
-
-
Tannock, I.F.1
De Wit, R.2
Berry, W.R.3
-
3
-
-
0034085989
-
Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients
-
Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31:578-83.
-
(2000)
Hum Pathol
, vol.31
, pp. 578-583
-
-
Bubendorf, L.1
Schopfer, A.2
Wagner, U.3
-
4
-
-
84885844885
-
Baseline covariates impacting overall survival (OS) in a phase III study of men with bone metastases from castration-resistant prostate cancer
-
abstr 4642
-
Fizazi K, Massard C, Smith MR, et al. Baseline covariates impacting overall survival (OS) in a phase III study of men with bone metastases from castration-resistant prostate cancer. J Clin Oncol. 2012:30(suppl):abstr 4642.
-
(2012)
J Clin Oncol
, vol.30
-
-
Fizazi, K.1
Massard, C.2
Smith, M.R.3
-
5
-
-
84898920356
-
Results of subset analyses on overall survival (OS) from study CA184-043: Ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC)
-
abstr 2
-
Drake CG, Kwon ED, Fizazi K, et al. Results of subset analyses on overall survival (OS) from study CA184-043: Ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2014:32(suppl 4):abstr 2.
-
(2014)
J Clin Oncol
, vol.32
-
-
Drake, C.G.1
Kwon, E.D.2
Fizazi, K.3
-
6
-
-
84914119103
-
The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials
-
abstr 5002
-
Halabi S, Kelly WK, Zhou H, et al. The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials. J Clin Oncol. 2014:32(suppl 5):abstr 5002.
-
(2014)
J Clin Oncol
, vol.32
-
-
Halabi, S.1
Kelly, W.K.2
Zhou, H.3
-
7
-
-
84878800972
-
Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases
-
Akfirat C, Zhang X, Ventura A, et al. Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases. J Pathol. 2013;230:291-7.
-
(2013)
J Pathol
, vol.230
, pp. 291-297
-
-
Akfirat, C.1
Zhang, X.2
Ventura, A.3
-
8
-
-
44449108773
-
Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases
-
Morrissey C, True LD, Roudier MP, et al. Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin Exp Metastasis. 2008;25:377-88.
-
(2008)
Clin Exp Metastasis
, vol.25
, pp. 377-388
-
-
Morrissey, C.1
True, L.D.2
Roudier, M.P.3
-
9
-
-
0034896088
-
Circulating transforming growth factor beta 1 as a predictor of liver metastasis after resection in colorectal cancer
-
Tsushima H, Ito N, Tamura S, et al. Circulating transforming growth factor beta 1 as a predictor of liver metastasis after resection in colorectal cancer. Clin Cancer Res. 2001;7:1258-62.
-
(2001)
Clin Cancer Res
, vol.7
, pp. 1258-1262
-
-
Tsushima, H.1
Ito, N.2
Tamura, S.3
-
10
-
-
44149106165
-
Serum markers for prostate cancer: A rational approach to the literature
-
Steuber T, O’Brien MF, Lilja H. Serum markers for prostate cancer: a rational approach to the literature. Eur Urol. 2008;54:31-40.
-
(2008)
Eur Urol
, vol.54
, pp. 31-40
-
-
Steuber, T.1
O’Brien, M.F.2
Lilja, H.3
-
11
-
-
0142008439
-
The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer
-
Kattan MW, Shariat SF, Andrews B, et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol. 2003;21:3573-79.
-
(2003)
J Clin Oncol
, vol.21
, pp. 3573-3579
-
-
Kattan, M.W.1
Shariat, S.F.2
Rews, B.3
-
12
-
-
84894085480
-
Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer
-
Goodman OB, Jr, Flaig TW, Molina A, et al. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2014;17:34-9.
-
(2014)
Prostate Cancer Prostatic Dis
, vol.17
, pp. 34-39
-
-
Goodman, O.B.1
Flaig, T.W.2
Molina, A.3
-
13
-
-
84894074281
-
Outcomes in patients with liver or lung metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial
-
abstr 5065
-
Loriot Y, Fizazi K, De Bono JS, et al. Outcomes in patients with liver or lung metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial. J Clin Oncol. 2013;31(suppl):abstr 5065.
-
(2013)
J Clin Oncol
, vol.31
-
-
Loriot, Y.1
Fizazi, K.2
De Bono, J.S.3
-
14
-
-
35948933892
-
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis
-
Armstrong AJ, Garrett-Mayer ES, Yang TC, et al. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res. 2007;13:6396-403.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 6396-6403
-
-
Armstrong, A.J.1
Garrett-Mayer, E.S.2
Yang, T.C.3
-
15
-
-
0038514138
-
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer
-
Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;21:1232-7.
-
(2003)
J Clin Oncol
, vol.21
, pp. 1232-1237
-
-
Halabi, S.1
Small, E.J.2
Kantoff, P.W.3
-
16
-
-
84890980389
-
Breathing new life into immunotherapy: Review of melanoma, lung and kidney cancer
-
Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol. 2014;11:24-37.
-
(2014)
Nat Rev Clin Oncol
, vol.11
, pp. 24-37
-
-
Drake, C.G.1
Lipson, E.J.2
Brahmer, J.R.3
-
17
-
-
77954939175
-
Prostate cancer as a model for tumour immunotherapy
-
Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol. 2010;10:580-93.
-
(2010)
Nat Rev Immunol
, vol.10
, pp. 580-593
-
-
Drake, C.G.1
-
18
-
-
84255197842
-
Cancer immunotherapy comes of age
-
Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480-9.
-
(2011)
Nature
, vol.480
, pp. 480-489
-
-
Mellman, I.1
Coukos, G.2
Dranoff, G.3
-
19
-
-
77955066199
-
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
-
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-22.
-
(2010)
N Engl J Med
, vol.363
, pp. 411-422
-
-
Kantoff, P.W.1
Higano, C.S.2
Shore, N.D.3
-
20
-
-
67650463335
-
Prostvac-VF: A vector-based vaccine targeting PSA in prostate cancer
-
Madan RA, Arlen PM, Mohebtash M, et al. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs. 2009;18:1001-11.
-
(2009)
Expert Opin Investig Drugs
, vol.18
, pp. 1001-1011
-
-
Madan, R.A.1
Arlen, P.M.2
Mohebtash, M.3
-
21
-
-
84858766182
-
The blockade of immune checkpoints in cancer immunotherapy
-
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-64.
-
(2012)
Nat Rev Cancer
, vol.12
, pp. 252-264
-
-
Pardoll, D.M.1
-
22
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-23.
-
(2010)
N Engl J Med
, vol.363
, pp. 711-723
-
-
Hodi, F.S.1
O’Day, S.J.2
McDermott, D.F.3
-
23
-
-
79959772576
-
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
-
Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517-26.
-
(2011)
N Engl J Med
, vol.364
, pp. 2517-2526
-
-
Robert, C.1
Thomas, L.2
Bondarenko, I.3
-
24
-
-
84879759020
-
Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma
-
Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma. N Engl J Med. 2013;369:134-44.
-
(2013)
N Engl J Med
, vol.369
, pp. 134-144
-
-
Hamid, O.1
Robert, C.2
Daud, A.3
-
25
-
-
84862859820
-
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
-
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-54.
-
(2012)
N Engl J Med
, vol.366
, pp. 2443-2454
-
-
Topalian, S.L.1
Hodi, F.S.2
Brahmer, J.R.3
-
26
-
-
84880508629
-
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: Results from an open-label, multicenter phase I/II study
-
Slovin SF, Higano CS, Hamid O, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol. 2013;24:1813-21.
-
(2013)
Ann Oncol
, vol.24
, pp. 1813-1821
-
-
Slovin, S.F.1
Higano, C.S.2
Hamid, O.3
-
27
-
-
84914115379
-
Sustained complete response to CTLA-4 blockade in a patient with metastatic, castration-resistant prostate cancer
-
Graff JN, Puri S, Bifulco CB, et al. Sustained complete response to CTLA-4 blockade in a patient with metastatic, castration-resistant prostate cancer. Cancer Immunol Res. 2014;2:399-403.
-
(2014)
Cancer Immunol Res
, vol.2
, pp. 399-403
-
-
Graff, J.N.1
Puri, S.2
Bifulco, C.B.3
-
28
-
-
12244252335
-
Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer
-
Demaria S, Kawashima N, Yang AM, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005;11:728-34.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 728-734
-
-
Demaria, S.1
Kawashima, N.2
Yang, A.M.3
-
29
-
-
84870659824
-
An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy
-
Antonarakis ES, Keizman D, Zhang Z, et al. An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer. 2012;118:6063-71.
-
(2012)
Cancer
, vol.118
, pp. 6063-6071
-
-
Antonarakis, E.S.1
Keizman, D.2
Zhang, Z.3
-
30
-
-
84914119102
-
Does tumor microenvironment affect the response of castration resistant prostate cancer to therapy in bone vs visceral metastases?
-
abstr MP49-15
-
Hiader M, Coleman I, Zhang X, et al. Does tumor microenvironment affect the response of castration resistant prostate cancer to therapy in bone vs visceral metastases? Proc Am Urological Assoc Annual Meeting. 2014;4(suppl):abstr MP49-15.
-
(2014)
Am Urological Assoc Annual Meeting
, vol.4
-
-
Hiader, M.1
Coleman, I.2
Zhang, X.3
-
31
-
-
84996525854
-
Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab
-
Yuan J, Zhou J, Dong Z, et al. Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res. 2014; 2:127-32.
-
(2014)
Cancer Immunol Res
, vol.2
, pp. 127-132
-
-
Yuan, J.1
Zhou, J.2
Dong, Z.3
-
32
-
-
34447117552
-
A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism
-
Manning EA, Ullman JG, Leatherman JM, et al. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res. 2007;13:3951-9.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 3951-3959
-
-
Manning, E.A.1
Ullman, J.G.2
Leatherman, J.M.3
-
33
-
-
84964313298
-
Bevacizumab plus ipilimumab in patients with metastatic melanoma
-
Hodi FS, Lawrence D, Lezcano C, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014;2:632-42.
-
(2014)
Cancer Immunol Res
, vol.2
, pp. 632-642
-
-
Hodi, F.S.1
Lawrence, D.2
Lezcano, C.3
-
34
-
-
78149298209
-
Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha
-
Kraman M, Bambrough PJ, Arnold JN, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science. 2010;330:827-30.
-
(2010)
Science
, vol.330
, pp. 827-830
-
-
Kraman, M.1
Bambrough, P.J.2
Arnold, J.N.3
-
35
-
-
65249138393
-
Myeloid-derived suppressor cells: Linking inflammation and cancer
-
Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182:4499-506.
-
(2009)
J Immunol
, vol.182
, pp. 4499-4506
-
-
Ostrand-Rosenberg, S.1
Sinha, P.2
-
36
-
-
33750807427
-
CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients
-
Miller AM, Lundberg K, Ozenci V, et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol. 2006;177:7398-405.
-
(2006)
J Immunol
, vol.177
, pp. 7398-7405
-
-
Miller, A.M.1
Lundberg, K.2
Ozenci, V.3
-
37
-
-
48849103649
-
Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing
-
Sfanos KS, Bruno TC, Maris CH, et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res. 2008;14:3254-61.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 3254-3261
-
-
Sfanos, K.S.1
Bruno, T.C.2
Maris, C.H.3
-
38
-
-
33744984785
-
Th17: An effector CD4 T cell lineage with regulatory T cell ties
-
Weaver CT, Harrington LE, Mangan PR, et al. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity. 2006;24:677-88.
-
(2006)
Immunity
, vol.24
, pp. 677-688
-
-
Weaver, C.T.1
Harrington, L.E.2
Mangan, P.R.3
-
39
-
-
84862016010
-
IL-6/IL-6R as a potential key signaling pathway in prostate cancer development
-
Azevedo A, Cunha V, Teixeira AL, Medeiros R. IL-6/IL-6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol. 2011;2:384-96.
-
(2011)
World J Clin Oncol
, vol.2
, pp. 384-396
-
-
Azevedo, A.1
Cunha, V.2
Teixeira, A.L.3
Medeiros, R.4
-
40
-
-
0037372374
-
Elevation of cytokine levels in cachectic patients with prostate carcinoma
-
Pfitzenmaier J, Vessella R, Higano CS, et al. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer. 2003;97:1211-6.
-
(2003)
Cancer
, vol.97
, pp. 1211-1216
-
-
Pfitzenmaier, J.1
Vessella, R.2
Higano, C.S.3
-
42
-
-
0023505508
-
Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines
-
Yoshimura T, Matsushima K, Tanaka S, et al. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci U S A. 1987;84:9233-7.
-
(1987)
Proc Natl Acad Sci U S A
, vol.84
, pp. 9233-9237
-
-
Yoshimura, T.1
Matsushima, K.2
Tanaka, S.3
-
43
-
-
84914119101
-
Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel
-
Oct 29. [Epub ahead of print]
-
Nuhn P, Vaghasia AM, Goyal J, et al. Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel. BJU Int. 2013 Oct 29. [Epub ahead of print]
-
(2013)
BJU Int
-
-
Nuhn, P.1
Vaghasia, A.M.2
Goyal, J.3
-
44
-
-
0036310021
-
Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma
-
Huang S, Mills L, Mian B, et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol. 2002;161:125-34.
-
(2002)
Am J Pathol
, vol.161
, pp. 125-134
-
-
Huang, S.1
Mills, L.2
Mian, B.3
-
46
-
-
84898920356
-
Results of subset analyses on overall survival (OS) from study CA184-043: Ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC)
-
abstr 2
-
Drake CG, Kwon ED, Fizazi K, et al. Results of subset analyses on overall survival (OS) from study CA184-043: ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2014;32(suppl 4):abstr 2.
-
(2014)
J Clin Oncol
, vol.32
-
-
Drake, C.G.1
Kwon, E.D.2
Fizazi, K.3
|